Epistra Inc. has been selected for the “FY2023 TOKYO Strategic Innovation Promotion Program” administered by the Tokyo Metropolitan Small and Medium Enterprise Support Center.
This program is a subsidy initiative that supports small and medium-sized enterprises in Tokyo in developing innovative technologies and products based on their core technologies by leveraging external knowledge and expertise, in accordance with the “Innovation Map.”
Subsidy Details:
- Maximum Amount: 80 million yen over three years
- Eligible Expenses: Raw materials, machinery and equipment, outsourcing, expert consulting, personnel costs, certification and registration, exhibition participation, advertising, and more
Our company will continue to advance AI-driven R&D efficiency for our automated experiment optimization system “Epistra Accelerate” using Bayesian optimization technology.
Related Articles
- Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of JapanEpistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
- Cell Culture Optimization Software 'CellTune Ver.2' Launches GloballyEpistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
- Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine SeminarOn June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.